By Elise Reuter
Published: October 15, 2026
A pivotal clinical study published in the New England Journal of Medicine has provided robust new evidence that continuous glucose monitoring (CGM) technology—specifically Dexcom’s G7 system—can fundamentally reshape the standard of care for millions of Americans living with Type 2 diabetes who do not rely on insulin. The findings arrive at a critical juncture as the industry awaits a landmark decision from the Centers for Medicare and Medicaid Services (CMS) regarding the expansion of coverage for these devices.
The Core Findings: Redefining Diabetes Management
The study, known as the "CONNECT" trial, enrolled 440 participants across 22 primary care practices throughout the United States. The methodology was straightforward yet rigorous: 145 participants were assigned to use the Dexcom G7 CGM, while a control group of 138 participants received routine standard-of-care monitoring.
The results were striking. Participants utilizing the CGM technology saw their HbA1c levels—a primary marker for long-term blood glucose control—plummet from an average baseline of 8.8% to 7.2% over the 26-week study period. In comparison, the control group saw a much more modest improvement, moving from an average of 8.7% to 8.0%.
Beyond the A1c metrics, the CGM group demonstrated a significant improvement in "time-in-range." On average, those using the G7 system spent five additional hours per day within the optimal blood glucose target range of 70 to 180 mg/dL. These metrics suggest that real-time data feedback allows patients to make more informed dietary and lifestyle decisions, effectively curbing the spikes and dips that characterize poorly managed diabetes.
Chronology: The Path to Clinical Validation
The journey toward this publication reflects the broader evolution of diabetes technology over the last decade. Historically, CGMs were reserved almost exclusively for patients with Type 1 diabetes, who require constant, precise monitoring to avoid life-threatening hypoglycemic events. However, as the prevalence of Type 2 diabetes has surged, the industry began pivoting toward non-insulin-dependent populations.
- Early 2024: Dexcom initiates the CONNECT study, aiming to address the "data gap" for non-insulin-using Type 2 patients.
- Mid-2025: Initial preliminary data points begin to circulate among industry analysts, hinting at significant improvements in glucose variability.
- Summer 2026: Competitive pressure mounts as Abbott, a primary rival in the space, signals that CMS coverage expansions could impact upwards of 10 million Medicare beneficiaries.
- October 15, 2026: The full results are published in the New England Journal of Medicine, providing the clinical "gold standard" validation required for regulatory and insurance policy shifts.
Supporting Data: Why Consistency Matters
One of the most compelling aspects of the CONNECT study was its demographic diversity. Dexcom reported that the benefits were consistent across a broad spectrum of variables, including age, sex, race, ethnicity, body mass index (BMI), diabetes duration, and even socioeconomic indicators such as education level and insurance type.
The study also highlighted high user engagement. Dr. Roy Beck, the study’s senior author and medical director of the JAEB Center for Health Research, noted that nearly all participants continued to use the CGM at the 26-week mark, with a majority checking their data daily. This high retention rate contradicts previous assumptions that patients without insulin-dependent regimens might find the technology too burdensome or "device-heavy" to sustain.
Leerink Partners analyst Mike Kratky, in a recent note to investors, emphasized that the data went beyond simple A1c reduction. Incremental analyses revealed a near-elimination of prolonged hyperglycemia in the CGM group. Furthermore, the study noted a higher rate of "medication intensification" among CGM users—essentially, the data allowed physicians and patients to realize earlier that lifestyle changes alone were insufficient, leading to faster, more effective adjustments in pharmaceutical regimens.
Official Responses and Industry Sentiment
The medical community and financial analysts have reacted to the publication with optimism, viewing it as a catalyst for a paradigm shift in primary care.
"The published study reinforces the strength and totality of the data," noted Mike Kratky. The findings are expected to be a cornerstone argument in Dexcom’s ongoing discussions with federal regulators.
Dr. Roy Beck offered a forward-looking perspective in a formal statement: "The consistency of benefit across a broad range of people and treatment regimens supports consideration of the use of a CGM much earlier in Type 2 diabetes management, before insulin is needed." By intervening earlier, the medical community hopes to prevent the long-term, costly complications of diabetes, such as neuropathy, retinopathy, and cardiovascular disease, which currently account for a massive portion of national healthcare spending.
Implications: The Medicare Horizon
The timing of this data release could not be more strategic. With roughly 25 million Americans living with Type 2 diabetes and not using insulin, the potential market for CGM adoption is massive.
The Medicare Coverage Expansion
The industry is currently holding its collective breath for a final decision from CMS. Analysts anticipate a decision before the end of the 2026 calendar year. Should CMS approve the expansion, implementation is expected by mid-2027.
The financial implications are staggering. Experts estimate that such a move could effectively double the number of covered lives for Dexcom, growing their total addressable market from 15 million to 30 million people. Abbott, having already positioned its own technology for this demographic, remains a significant player, with estimates suggesting their coverage reach could similarly expand by 10 million beneficiaries.
A Shift in Primary Care
Beyond the business metrics, the implication for primary care is profound. For decades, the primary care model for Type 2 diabetes was reactive: monitor A1c every three to six months, adjust medication, and repeat. The adoption of CGM represents a move toward proactive, data-driven management.
By empowering patients to see the real-time impact of their behavior on their glucose levels, the medical community is moving away from the "one-size-fits-all" approach to a more personalized medicine model. As these devices become more affordable and accessible via expanded insurance coverage, the "standard of care" may soon shift from periodic finger-prick testing to continuous, actionable data streams.
Conclusion: A New Standard?
The CONNECT study has successfully bridged the gap between clinical efficacy and practical, real-world application. By demonstrating that CGM technology is not only effective but also universally beneficial regardless of a patient’s background, Dexcom has cleared a major hurdle in the fight to democratize diabetes care.
As the industry moves toward 2027, the focus will now shift from the question of if these devices work to how to implement them at scale. With CMS in the driver’s seat, the upcoming months will determine whether this technological leap becomes a standard feature of American healthcare or remains an inaccessible luxury for those who could benefit from it most. One thing is clear: the data presented today has set a new benchmark for what is possible in the management of chronic disease.
